Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3609078 | 0.89 | KDM4E (0.35) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3602704 | 0.86 | KDM4E (0.42) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3602358 | 0.85 | KDM4E (0.37) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3602944 | 0.84 | MCL1 (0.37) | GPBAR1KDM4EALDH1A1MAPT | |
| SCHEMBL3600965 | 0.83 | KDM4E (0.35) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3604938 | 0.82 | KDM4E (0.42) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3604317 | 0.82 | KDM4E (0.42) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3611040 | 0.82 | KDM4E (0.44) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3593934 | 0.81 | KDM4E (0.39) | GPBAR1KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL3608530 | 0.81 | TSHR (0.45) | GPBAR1KDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128138-A1 | PYRAZOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016396-A1 | PYRAZOLE COMPOUND | SLC5A1, SLC5A2, GLP1R | GPBAR1 730/4885KDM4E 2049/4885ALDH1A1 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.